Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Jade Biosciences reported positive interim Phase 1 results for JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy treatment. The drug demonstrated ~70% IgA reductions sustained at 12 weeks with a favorable safety profile and potential for every-12-week dosing. Phase 2 trials are underway with Phase 3 expected to initiate in H1 2027.